{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:59:13Z","timestamp":1790035153023,"version":"4.0.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Associazione Italiana per la Ricerca sul Cancro","award":["IG-ID 30522 to MPM"],"award-info":[{"award-number":["IG-ID 30522 to MPM"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00277-025-06500-0","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T03:59:58Z","timestamp":1751947198000},"page":"4267-4271","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Venetoclax plus azacitidine as genetic-driven bridge-to-transplant therapy for IDH2-mutated acute myeloid leukaemia (AML) refractory to intensive chemotherapy: proof-of-concept case reports"],"prefix":"10.1007","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4879-7824","authenticated-orcid":false,"given":"Gaetano","family":"Cimino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Caridi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Cardinali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Sciabolacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Rellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Matteucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mecucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Sportoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Zorutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Carotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"La Starza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pierini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9139-1729","authenticated-orcid":false,"given":"Maria Paola","family":"Martelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"6500_CR1","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP et al (2022) International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 140:1200\u20131228. https:\/\/doi.org\/10.1182\/blood.2022015850","journal-title":"Blood"},{"key":"6500_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140:1345\u20131377. https:\/\/doi.org\/10.1182\/blood.2022016867","journal-title":"Blood"},{"key":"6500_CR3","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383:617\u2013629. https:\/\/doi.org\/10.1056\/NEJMoa2012971","journal-title":"N Engl J Med"},{"key":"6500_CR4","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Tiong IS, Quaglieri A et al (2020) Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood 135:791\u2013803. https:\/\/doi.org\/10.1182\/blood.2019003988","journal-title":"Blood"},{"key":"6500_CR5","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-21-3467","volume":"28","author":"DA Pollyea","year":"2022","unstructured":"Pollyea DA, DiNardo CD, Arellano ML et al (2022) Impact of venetoclax and Azacitidine in Treatment-Na\u00efve patients with acute myeloid leukemia and IDH1\/2 mutations. Clin Cancer Res 28:2753\u20132761. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3467","journal-title":"Clin Cancer Res"},{"key":"6500_CR6","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1182\/blood.2024025409","volume":"144","author":"H D\u00f6hner","year":"2024","unstructured":"D\u00f6hner H, DiNardo CD, Appelbaum FR et al (2024) Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood 144:2169\u20132173. https:\/\/doi.org\/10.1182\/blood.2024025409","journal-title":"Blood"},{"key":"6500_CR7","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"TJ Ley","year":"2013","unstructured":"Cancer Genome Atlas Research Network, Ley TJ, Miller C et al (2013) Genomic and epigenomic landscapes of adult de Novo acute myeloid leukemia. N Engl J Med 368:2059\u20132074. https:\/\/doi.org\/10.1056\/NEJMoa1301689","journal-title":"N Engl J Med"},{"key":"6500_CR8","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nm.3788","volume":"21","author":"SM Chan","year":"2015","unstructured":"Chan SM, Thomas D, Corces-Zimmerman MR et al (2015) Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med 21:178\u2013184. https:\/\/doi.org\/10.1038\/nm.3788","journal-title":"Nat Med"},{"key":"6500_CR9","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1002\/cncr.34608","volume":"129","author":"E Todisco","year":"2023","unstructured":"Todisco E, Papayannidis C, Fracchiolla N et al (2023) AVALON: the Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed\/refractory patients with acute myeloid leukemia. Cancer 129:992\u20131004. https:\/\/doi.org\/10.1002\/cncr.34608","journal-title":"Cancer"},{"key":"6500_CR10","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1111\/bjh.16722","volume":"192","author":"IS Tiong","year":"2021","unstructured":"Tiong IS, Dillon R, Ivey A et al (2021) Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia. Br J Haematol 192:1026\u20131030. https:\/\/doi.org\/10.1111\/bjh.16722","journal-title":"Br J Haematol"},{"key":"6500_CR11","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/bjh.18887","volume":"202","author":"C Sartor","year":"2023","unstructured":"Sartor C, Brunetti L, Audisio E et al (2023) A venetoclax and Azacitidine bridge-to\u2010transplantstrategy for NPM1\u2010mutated acute myeloid leukaemia in molecular failure. Br J Haematol 202:599\u2013607. https:\/\/doi.org\/10.1111\/bjh.18887","journal-title":"Br J Haematol"},{"key":"6500_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood.2023022481","volume":"143","author":"F Thol","year":"2024","unstructured":"Thol F, D\u00f6hner H, Ganser A (2024) How I treat refractory and relapsed acute myeloid leukemia. Blood 143:11\u201320. https:\/\/doi.org\/10.1182\/blood.2023022481","journal-title":"Blood"},{"key":"6500_CR13","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1182\/blood-2014-03-564401","volume":"124","author":"MF Martelli","year":"2014","unstructured":"Martelli MF, Di Ianni M, Ruggeri L et al (2014) HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. Blood 124:638\u2013644. https:\/\/doi.org\/10.1182\/blood-2014-03-564401","journal-title":"Blood"},{"key":"6500_CR14","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1182\/bloodadvances.2020003739","volume":"5","author":"A Pierini","year":"2021","unstructured":"Pierini A, Ruggeri L, Carotti A et al (2021) Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia. Blood Adv 5:1199\u20131208. https:\/\/doi.org\/10.1182\/bloodadvances.2020003739","journal-title":"Blood Adv"},{"key":"6500_CR15","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L et al (2016) Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 374:2209\u20132221. https:\/\/doi.org\/10.1056\/NEJMoa1516192","journal-title":"N Engl J Med"},{"key":"6500_CR16","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE et al (2019) Gilteritinib or chemotherapy for relapsed or refractory FLT3-Mutated AML. N Engl J Med 381:1728\u20131740. https:\/\/doi.org\/10.1056\/NEJMoa1902688","journal-title":"N Engl J Med"},{"key":"6500_CR17","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1182\/blood-2022-169351","volume":"140","author":"A Pierini","year":"2022","unstructured":"Pierini A, Ruggeri L, Saldi S et al (2022) HLA-Matched treg\/tcon allogeneic hematopoietic cell transplantation is safe and ensures remarkable chronic gvhd\/leukemia free survival in High-Risk leukemia patients. Blood 140:2133\u20132134. https:\/\/doi.org\/10.1182\/blood-2022-169351","journal-title":"Blood"},{"key":"6500_CR18","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.3324\/haematol.2016.148825","volume":"101","author":"P Ferguson","year":"2016","unstructured":"Ferguson P, Hills RK, Grech A et al (2016) An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who May benefit from allogeneic stem cell transplantation. Haematologica 101:1351\u20131358. https:\/\/doi.org\/10.3324\/haematol.2016.148825","journal-title":"Haematologica"},{"key":"6500_CR19","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.3324\/haematol.2018.203869","volume":"104","author":"R Ram","year":"2019","unstructured":"Ram R, Scheid C, Amit O et al (2019) Sequential therapy for patients with primary refractory acute myeloid leukemia: a historical prospective analysis of the German and Israeli experience. Haematologica 104:1798\u20131803. https:\/\/doi.org\/10.3324\/haematol.2018.203869","journal-title":"Haematologica"},{"key":"6500_CR20","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3324\/haematol.2016.159343","volume":"102","author":"SA Buckley","year":"2017","unstructured":"Buckley SA, Wood BL, Othus M et al (2017) Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica 102:865\u2013873. https:\/\/doi.org\/10.3324\/haematol.2016.159343","journal-title":"Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06500-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06500-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06500-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T07:48:36Z","timestamp":1757663316000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06500-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["6500"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06500-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"assertion":[{"value":"11 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. The study was approved by the local institutional review board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"Written informed consent was obtained from all the subjects for participation in this study and publication of this article and any further research issues.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Maria Paola Martelli declares honoraria\/consultancy at the scientific advisory board for Abbvie, Amgen, Be-One, BMS, Delbert, Janssen, Novartis, Pfizer, and Jazz Pharmaceuticals. The other authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}